Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

Angelique G. S. C. Jansen*, Gerwin D. Rodenburg, Sabine C. de Greeff, Eelko Hak, Reinier H. Veenhoven, Lodewijk Spanjaard, Leo M. Schouls, Elisabeth A. M. Sanders, Arie van der Ende

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    58 Citaten (Scopus)

    Samenvatting

    With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for similar to 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons >= 90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy. (C) 2009 Elsevier Ltd. All rights reserved.

    Originele taal-2English
    Pagina's (van-tot)2394-2401
    Aantal pagina's8
    TijdschriftVaccine
    Volume27
    Nummer van het tijdschrift17
    DOI's
    StatusPublished - 14-apr-2009

    Citeer dit